ArticleOncoimmunology
TNFR2: The new Treg switch?
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026Review
- Stress-Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor necrosis factor receptor 2 in allergen tolerance: a perspective view.Frontiers in immunology · 2025Review
- The distinctive signature of regulatory CD4 T cells committed in the human thymus.Frontiers in immunology · 2025Article
- TNF Superfamily and ILC2 Activation in Asthma.Biomolecules · 2024Review
- Bistability regulates TNFR2-mediated survival and death of T-regulatory cells.Journal of biological physics · 2023Article
- A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma.Journal of translational medicine · 2022Article
- Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Immunosuppression in Malaria: DoPathogens (Basel, Switzerland) · 2021Review
- TNFR2: Role in Cancer Immunology and Immunotherapy.ImmunoTargets and therapy · 2021Review
- The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.Frontiers in cell and developmental biology · 2021Review
- Biomarkers for Temporomandibular Disorders: Current Status and Future Directions.Diagnostics (Basel, Switzerland) · 2020Review
- The Role of TNFR2 and DR3 in the In Vivo Expansion of Tregs in T Cell Depleting Transplantation Regimens.International journal of molecular sciences · 2020Review
- TNFR2 Signaling Enhances ILC2 Survival, Function, and Induction of Airway Hyperreactivity.Cell reports · 2019Article
- Article
- A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy.Journal of oncology · 2019Review
- Overexpression of KLF14 protects against immune-mediated hepatic injury in mice.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Evidence revealing the role of T cell regulators (Tregs) in periodontal diseases: A review.Journal of Indian Society of PeriodontologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TNF/TNR2 pathway as a swith and as a new target for immune checkpoint therapy to modulate the immune regulation in this clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.